title: [Preliminary results of conservative combination radiotherapy and chemotherapy in early stages of Hodgkin's disease].
abstract: 20 patients in early stages (I-IIB) Hodgkin's disease were treated with smaller than commonly used doses of cytostatics and radiation. Men were given EBVD-CVPP-EBVD (epirubicin, bleomycin, vinblastine, DTIC, cyclophosphamide, vinblastine, procarbazine, prednisone) and women: CVPP-EBVD-CVPP. Radiotherapy was limited to involved and adjacent fields. In all patients complete remission was achieved lasting now 9 to 107 months (mean 55 months). Two patients relapsed. No undesirable early side effects were observed. Further observations will show if such therapeutic option in non-advanced Hodgkin's disease is sufficient.
authors.affiliation: Katedry i Kliniki Hematologii i Chorób Rozrostowych A.M.
authors.forename: K
authors.initials: K
authors.lastname: Gabryś
authors.forename: D
authors.initials: D
authors.lastname: Urbaniak-Kujda
authors.forename: R
authors.initials: R
authors.lastname: Dubowik
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011829:Radiation Dosage; D012074:Remission Induction; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D011344:Procarbazine; D015251:Epirubicin; D014747:Vinblastine; D003606:Dacarbazine; D003520:Cyclophosphamide; D011241:Prednisone
vernacular_title: Wstepne wyniki oszczednej, kombinowanej radioterapii i chemioterapii wczesnych stadiów choroby Hodgkina.